WallStSmart

20/20 Biolabs, Inc. Common Stock (AIDX)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 1971169% more annual revenue ($36.36B vs $1.84M). MDT leads profitability with a 13.2% profit margin vs -279.1%. MDT earns a higher WallStSmart Score of 62/100 (C+).

AIDX

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 6.3
Piotroski: 3/9

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AIDX.

MDTUndervalued (+12.0%)

Margin of Safety

+12.0%

Fair Value

$91.98

Current Price

$78.23

$13.75 discount

UndervaluedFair: $91.98Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIDX2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$103.66B9/10

Large-cap with strong market position

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.1%8/10

Strong operational efficiency at 22.1%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

AIDX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.97M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-354.6%2/10

ROE of -354.6% — below average capital efficiency

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AIDX

The strongest argument for AIDX centers on Debt/Equity, Price/Book.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : AIDX

The primary concerns for AIDX are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

AIDX profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.60 — expect wider price swings.

MDT is growing revenue faster at 9.9% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (62/100 vs 21/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

20/20 Biolabs, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

20/20 Biolabs, Inc. (AIDX) is an innovative biotechnology firm committed to revolutionizing genomic research and diagnostics through its advanced laboratory services. With a keen focus on enhancing the accuracy and efficiency of genetic testing for clinical and research purposes, the company is poised to be a leader in the molecular diagnostics landscape. By leveraging state-of-the-art technologies, 20/20 Biolabs is strategically positioned to capitalize on the growing demand for personalized medicine and genomic data. Its strong market presence and forward-thinking initiatives underscore a compelling growth outlook within the rapidly evolving biotechnology sector.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?